Insmed (INSM) Reports Q4 Loss of $0.85/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
February 23, 2018 7:30 AM ESTOn track to file NDA before the end of March and anticipate a priority reviewExtended amikacin liposome inhalation suspension (ALIS) intellectual property protection to 2035 with issuance of ninth U.S. patentStrengthened cash position through the public offering of $450 million of convertible senior notes in January 2018 Completed the hiring of 71 therapeutic specialists and 5 key account directors to support disease state awareness efforts in the U.S.
BRIDGEWATER, N.J., Feb. 23, 2018 (GLOBE... More
